Literature DB >> 23361977

Carboxylic acid (bio)isosteres in drug design.

Carlo Ballatore1, Donna M Huryn, Amos B Smith.   

Abstract

The carboxylic acid functional group can be an important constituent of a pharmacophore, however, the presence of this moiety can also be responsible for significant drawbacks, including metabolic instability, toxicity, as well as limited passive diffusion across biological membranes. To avoid some of these shortcomings while retaining the desired attributes of the carboxylic acid moiety, medicinal chemists often investigate the use of carboxylic acid (bio)isosteres. The same type of strategy can also be effective for a variety other purposes, for example, to increase the selectivity of a biologically active compound or to create new intellectual property. Several carboxylic acid isosteres have been reported, however, the outcome of any isosteric replacement cannot be readily predicted as this strategy is generally found to be dependent upon the particular context (i.e., the characteristic properties of the drug and the drug-target). As a result, screening of a panel of isosteres is typically required. In this context, the discovery and development of novel carboxylic acid surrogates that could complement the existing palette of isosteres remains an important area of research. The goal of this Minireview is to provide an overview of the most commonly employed carboxylic acid (bio)isosteres and to present representative examples demonstrating the use and utility of each isostere in drug design.
Copyright © 2013 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23361977      PMCID: PMC3640829          DOI: 10.1002/cmdc.201200585

Source DB:  PubMed          Journal:  ChemMedChem        ISSN: 1860-7179            Impact factor:   3.466


  63 in total

1.  The hydrogen bond environments of 1H-tetrazole and tetrazolate rings: the structural basis for tetrazole-carboxylic acid bioisosterism.

Authors:  Frank H Allen; Colin R Groom; John W Liebeschuetz; David A Bardwell; Tjelvar S G Olsson; Peter A Wood
Journal:  J Chem Inf Model       Date:  2012-02-21       Impact factor: 4.956

2.  Synthesis and biological evaluation of 2-(3'-(1H-tetrazol-5-yl) bicyclo[1.1.1]pent-1-yl)glycine (S-TBPG), a novel mGlu1 receptor antagonist.

Authors:  G Costantino; K Maltoni; M Marinozzi; E Camaioni; L Prezeau; J P Pin; R Pellicciari
Journal:  Bioorg Med Chem       Date:  2001-02       Impact factor: 3.641

Review 3.  Thiazolidinediones in the treatment of insulin resistance and type II diabetes.

Authors:  A R Saltiel; J M Olefsky
Journal:  Diabetes       Date:  1996-12       Impact factor: 9.461

Review 4.  A new class of diacidic nonpeptide angiotensin II receptor antagonists: candesartan cilexetil.

Authors:  T Naka; K Kubo
Journal:  Curr Pharm Des       Date:  1999-06       Impact factor: 3.116

5.  Unusually weak binding interactions in tetrazole-amidine complexes.

Authors:  Alan F Tominey; Paul H Docherty; Georgina M Rosair; Romain Quenardelle; Arno Kraft
Journal:  Org Lett       Date:  2006-03-30       Impact factor: 6.005

6.  3'-(Arylmethyl)- and 3'-(aryloxy)-3-phenyl-4-hydroxyquinolin-2(1H)-ones: orally active antagonists of the glycine site on the NMDA receptor.

Authors:  J J Kulagowski; R Baker; N R Curtis; P D Leeson; I M Mawer; A M Moseley; M P Ridgill; M Rowley; I Stansfield; A C Foster
Journal:  J Med Chem       Date:  1994-05-13       Impact factor: 7.446

7.  2,3-Diarylthiophenes as selective EP1 receptor antagonists.

Authors:  Yves Ducharme; Marc Blouin; Marie-Claude Carrière; Anne Chateauneuf; Bernard Côté; Danielle Denis; Richard Frenette; Gillian Greig; Stacia Kargman; Sonia Lamontagne; Evelyn Martins; François Nantel; Gary O'Neill; Nicole Sawyer; Kathleen M Metters; Richard W Friesen
Journal:  Bioorg Med Chem Lett       Date:  2005-02-15       Impact factor: 2.823

8.  Synthesis and angiotensin II receptor antagonistic activities of benzimidazole derivatives bearing acidic heterocycles as novel tetrazole bioisosteres.

Authors:  Y Kohara; K Kubo; E Imamiya; T Wada; Y Inada; T Naka
Journal:  J Med Chem       Date:  1996-12-20       Impact factor: 7.446

9.  Discovery of 5-aryloxy-2,4-thiazolidinediones as potent GPR40 agonists.

Authors:  Changyou Zhou; Cheng Tang; Eric Chang; Min Ge; Songnian Lin; Eric Cline; Carina P Tan; Yue Feng; Yun-Ping Zhou; George J Eiermann; Aleksandr Petrov; Gino Salituro; Peter Meinke; Ralph Mosley; Taro E Akiyama; Monica Einstein; Sanjeev Kumar; Joel Berger; Andrew D Howard; Nancy Thornberry; Sander G Mills; Lihu Yang
Journal:  Bioorg Med Chem Lett       Date:  2009-10-15       Impact factor: 2.823

Review 10.  Role of tau protein in both physiological and pathological conditions.

Authors:  Jesus Avila; Jose J Lucas; Mar Perez; Felix Hernandez
Journal:  Physiol Rev       Date:  2004-04       Impact factor: 37.312

View more
  68 in total

1.  Rickettsia prowazekii methionine aminopeptidase as a promising target for the development of antibacterial agents.

Authors:  Travis R Helgren; Congling Chen; Phumvadee Wangtrakuldee; Thomas E Edwards; Bart L Staker; Jan Abendroth; Banumathi Sankaran; Nicole A Housley; Peter J Myler; Jonathon P Audia; James R Horn; Timothy J Hagen
Journal:  Bioorg Med Chem       Date:  2016-11-10       Impact factor: 3.641

2.  Efficacy and cytotoxicity in cell culture of novel α-hydroxytropolone inhibitors of hepatitis B virus ribonuclease H.

Authors:  Elena Lomonosova; Jil Daw; Aswin K Garimallaprabhakaran; Nana B Agyemang; Yashkumar Ashani; Ryan P Murelli; John E Tavis
Journal:  Antiviral Res       Date:  2017-06-17       Impact factor: 5.970

3.  Decarboxylative borylation.

Authors:  Chao Li; Jie Wang; Lisa M Barton; Shan Yu; Maoqun Tian; David S Peters; Manoj Kumar; Antony W Yu; Kristen A Johnson; Arnab K Chatterjee; Ming Yan; Phil S Baran
Journal:  Science       Date:  2017-04-13       Impact factor: 47.728

4.  Assessing the Conformational Equilibrium of Carboxylic Acid via Quantum Mechanical and Molecular Dynamics Studies on Acetic Acid.

Authors:  Victoria T Lim; Christopher I Bayly; Laszlo Fusti-Molnar; David L Mobley
Journal:  J Chem Inf Model       Date:  2019-02-21       Impact factor: 4.956

5.  Minimizing the Contribution of Enterohepatic Recirculation to Clearance in Rat for the NCINI Class of Inhibitors of HIV.

Authors:  Lee D Fader; Rebekah Carson; Sébastien Morin; François Bilodeau; Catherine Chabot; Ted Halmos; Murray D Bailey; Stephen H Kawai; René Coulombe; Steven Laplante; Kevork Mekhssian; Araz Jakalian; Michel Garneau; Jianmin Duan; Stephen W Mason; Bruno Simoneau; Craig Fenwick; Youla Tsantrizos; Christiane Yoakim
Journal:  ACS Med Chem Lett       Date:  2014-04-16       Impact factor: 4.345

6.  Structure-Activity Relationships in Metal-Binding Pharmacophores for Influenza Endonuclease.

Authors:  Cy V Credille; Benjamin L Dick; Christine N Morrison; Ryjul W Stokes; Rebecca N Adamek; Nicholas C Wu; Ian A Wilson; Seth M Cohen
Journal:  J Med Chem       Date:  2018-10-31       Impact factor: 7.446

Review 7.  1,2,4-Triazolo[1,5-a]pyrimidines in drug design.

Authors:  Killian Oukoloff; Bobby Lucero; Karol R Francisco; Kurt R Brunden; Carlo Ballatore
Journal:  Eur J Med Chem       Date:  2019-01-14       Impact factor: 6.514

Review 8.  Tetrazoles via Multicomponent Reactions.

Authors:  Constantinos G Neochoritis; Ting Zhao; Alexander Dömling
Journal:  Chem Rev       Date:  2019-02-01       Impact factor: 60.622

9.  Carboxylate Surrogates Enhance the Antimycobacterial Activity of UDP-Galactopyranose Mutase Probes.

Authors:  Valerie J Winton; Claudia Aldrich; Laura L Kiessling
Journal:  ACS Infect Dis       Date:  2016-06-29       Impact factor: 5.084

10.  LAT1 activity of carboxylic acid bioisosteres: Evaluation of hydroxamic acids as substrates.

Authors:  Arik A Zur; Huan-Chieh Chien; Evan Augustyn; Andrew Flint; Nathan Heeren; Karissa Finke; Christopher Hernandez; Logan Hansen; Sydney Miller; Lawrence Lin; Kathleen M Giacomini; Claire Colas; Avner Schlessinger; Allen A Thomas
Journal:  Bioorg Med Chem Lett       Date:  2016-09-03       Impact factor: 2.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.